Werbung
Werbung
KROS
Keros Therapeutics, Inc. Common Stock
19.19
USDGesponsert
+0.61
+3.29%
09. Jan., 15:59 UTC -5
Geschlossen
Nach-Markt
18.96
-0.23
-1.21%
KROS Ergebnisberichte
Positives Überraschungsverhältnis
KROS übertreffen die 14 der letzten 23Schätzungen.
61%
Nächster Bericht
Datum des nächsten Berichts
24. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.81M
/-$0.60
Implizierte Änderung von Q3 25 (Revenue/ EPS)
-80.28%
/+233.33%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
-7.55%
/-46.90%
Keros Therapeutics, Inc. Common Stock earnings per share and revenue
On 05. Nov. 2025, KROS reported earnings of -0.18 USD per share (EPS) for Q3 25, beating the estimate of -1.06 USD, resulting in a 83.14% surprise. Revenue reached 14.26 million, compared to an expected 3.88 million, with a 267.96% difference. The market reacted with a +3.32% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.60 USD, with revenue projected to reach 2.81 million USD, implying an increase of 233.33% EPS, and decrease of -80.28% in Revenue from the last quarter.
FAQ
What were Keros Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Keros Therapeutics, Inc. Common Stock reported EPS of -$0.18, beating estimates by 83.14%, and revenue of $14.26M, 267.96% above expectations.
How did the market react to Keros Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 3.32%, changed from $15.65 before the earnings release to $16.17 the day after.
When is Keros Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 24. Feb. 2026.
What are the forecasts for Keros Therapeutics, Inc. Common Stock's next earnings report?
Based on 12
analysts, Keros Therapeutics, Inc. Common Stock is expected to report EPS of -$0.60 and revenue of $2.81M for Q4 2025.
Which companies are reporting earnings today?
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung